Lancet HIV

Papers
(The H4-Index of Lancet HIV is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Optimising anal cancer screening through risk stratification490
How do we prevent anal cancer in people living with HIV?170
Evidence supports use of on-demand PrEP for HIV prevention157
Lung cancer in people living with HIV151
Argentina updates HIV laws129
Transplant donation without discrimination129
How much could long-acting PrEP cost in South Africa?127
Controversial chronicler of LGBTQ rights113
Correction to Lancet HIV 2022; 9: e791–800108
Risk estimation in HIV reveals our usual blind spots103
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c85
A moment of reckoning83
Lenacapavir: an attractive option, but proceed with caution77
Are we ready for long-acting HIV treatment for adolescents?75
Steps toward quick and equitable roll-out of lenacapavir71
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia 71
The caveats of short-cycle antiretroviral therapy in adolescents living with HIV68
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma66
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial66
Growing old and well with HIV64
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial62
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial58
Viral load data from South Africa builds confidence in U=U58
Redefining care: injectable HIV treatment for adolescents57
All roads lead to Westminster: the infected blood scandal57
Making America unhealthy again56
Recent gay Black history in the UK54
Reducing HIV transmission in British Columbia, Canada52
Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa:51
Standardisation of monitoring routines for new long-acting antiretrovirals in development49
Unheard testimony49
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries48
WHO recommends lenacapavir for HIV prevention48
Sex as a biological variable in HIV-1 and schistosome co-infection46
Preventing tuberculosis in advanced HIV disease46
The impact of HIV stigma and discrimination on HIV testing, antiretroviral treatment, and viral suppression in Africa: a pooled analysis of population-based surveys46
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study43
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther43
Integration of sexual health and HIV services39
Suicide prevention research is crucial to achieving health equity for people with HIV39
Lateral flow assay-based CD4 cell count testing for advanced HIV disease39
0.8027868270874